BTZ is approved for the treatment of multiple myeloma and mantle cell lymphoma (Stapnes et al., 2007) and has been explored in early phase clinical studies for GBM (Kubicek et al., 2009; Friday et al., 2012; Bota et al., 2013; Kong et al., 2018; Rahman et al., 2020). This evidence concerns the gene CASC3 and plasma cell myeloma.